SPOTLIGHT: FDA to give Humira priority review for Crohn's

Abbott Laboratories [1] says that the FDA will give its anti-inflammatory drug Humira [2] a priority review as a treatment for Crohn's disease. The priority review will move up a decision on Humira into early March, cutting four months off the timetable. To back up its application for Humira, Abbott submitted data from a trial of volunteers who had not responded to the monoclonal antibody Remicade [3] (infliximab) made by Centocor [4]. In Crohn's disease inflammation of the digestive tract causes pain and diarrhea. Humira has already been approved for rheumatoid arthritis and other conditions. Report [5]